top of page
  • Writer's pictureAkthelia News Desk

Dr Sonja Srdanović joins Akthelia Pharma as R&D Program Manager for Inflammation and Infection

REYKJAVIK, Iceland -- 27 November, 2023 -- Akthelia Pharmaceuticals, a biopharma company, with a first-in-class immunotherapeutic approach, is pleased to announce the appointment of Dr Sonja Srdanović joins Akthelia Pharma as R&D Program Manager for Inflammation and Infection.

Prior to joining Akthelia, Dr Srdanović held the position of Senior Scientist in Alvotech, where she supported analytical development programs in production of biologic medicines. Before that, during her time with 3Z Pharmaceuticals, she managed high-throughput preclinical drug screening projects using zebrafish, with a primary focus on advancing drug discovery in the field of CNS disorders.

"We are delighted to have Sonja joining our expanding team" commented Egill Masson, CEO of Akthelia Pharma, "Sonja brings a wealth of experience to Akthelia and will play a critical role in driving forward our exciting projects in inflammation and infection."

Sonja's vast experience in highly interdisciplinary research and her background in chemical biology is particularly relevant to Akthelia's participation in the EU Horizon funded IN-ARMOR PROJECT.

Sonja holds a PhD in chemical biology from the University of Leeds where she worked as an ESR Fellow and gained extensive experience in developing new methods to modulate protein-protein interactions for drug discovery.

Dr Sonja Srdanović, R&D Program Manager for Inflammation and Infection
Dr Sonja Srdanović, R&D Program Manager for Inflammation and Infection



Akthelia Pharmaceuticals - Leading the Science of Our Surfaces™️ - is a preclinical-stage biopharma company with a next-generation immunotherapeutic strategy to upregulate the innate immunology of epithelial surfaces. This novel approach has application potential to many areas of medicine and addresses the growing threat of antibiotic bacterial resistance (AMR) worldwide.

Akthelia’s lead therapeutic program upregulates the innate immunology in the GI tract, blocking leakage of microbiota to improve outcomes in cancer care through reducing the risk of neutropenia, a common and severe complication in chemotherapy and immunocompromised patients.


The IN-ARMOR project brings together nine universities, research institutes, and seven medical and industry partners across nine EU countries. The project’s goal is to introduce a novel class of immune system inducers to enhance the body’s innate microbial defense mechanisms, combating AMR and reducing the incidence of 13 of the most dangerous infections, including two of the top three priority-1 infections. Horizon Europe is the EU’s key funding program for research and innovation with a budget of €95.5 billion.

Employing computer-aided drug design and in-silico approaches, alongside a nanotech-based drug delivery system, IN-ARMOR will optimize an existing drug platform for its first target indication. The therapy will undergo pre-clinical validation for safety and efficacy, meeting all investigational medicinal product requirements.

Upon completion, IN-ARMOR will advance to clinical validation, with the potential to save over 4 million lives worldwide and significantly reduce the burden of antibiotic development, leading to long-term cost reduction impact of €107BN and reduction in global disease burden of 97 million DALYs.




Akthelia Pharmaceuticals Grandagarði 16 101 Reykjavik Iceland


bottom of page